Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-291
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ABBV-291 is an investigational antineoplastic drug being developed by AbbVie for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia. It is currently in Phase 1 clinical trials to determine its safety profile, pharmacokinetics, and efficacy in adults who have failed at least two prior lines of therapy. The precise mechanism of action has not been publicly defined as of the latest updates, but it is classified broadly as an antineoplastic agent. The drug is administered intravenously and trial participants are monitored for adverse events and changes in disease activity over a multi-year study period.
- Other names
- ABBV 291ABBV291ABBV-291
Beyond the preview
Go deeper on ABBV-291.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-291.